Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
200 Technology Square
Cambridge, MA
Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

  • Featured Employer

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines.

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.
We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.
NEWS
Promosome filed lawsuits Tuesday against Moderna and Pfizer/BioNTech, alleging that the vaccine developers used patent-protected mRNA technology without a license.
As the COVID-19 market dries up, Moderna looks to FDA approval of its other vaccines including a 2024 commercial launch of its investigational RSV vaccine for older adults.
Cancer vaccines enjoyed a moment in the spotlight this week as Moderna, Merck, Nykode Therapeutics and Transgene shared promising updates at AACR and beyond.
Moderna claims it can have vaccines ready for multiple cancer types by 2030, but experts say challenges remain.
Roche, AstraZeneca, Moderna, Merck and Affimed presented new data in liver cancer, lung cancer, melanoma and lymphoma.
The lawsuit, brought by Arbutus Biopharma, marks the latest legal action in an ongoing battle for intellectual property underlying mRNA vaccines for COVID-19.
An interim analysis of the Phase III P302 study showed Moderna’s investigational flu shot, mRNA-1010, fell short of the statistical threshold for early success.
There have already been several big biotech licensing deals in Q1. See inside for some of this quarter’s biggest licensing deals — from the surprising and pivotal to the lucrative and consequential.
As demand for biotech talent increases, the need to offer competitive pay to the average employee puts financial pressure on companies to increase CEO pay as well.
JOBS
  • 20251103 - FINAL PROOF - 2026 HOTBED MAPS - GENETOWN - Moderna.png
IN THE PRESS